Diversify Wealth Management LLC Acquires 10,630 Shares of Zoetis Inc. (NYSE:ZTS)

Diversify Wealth Management LLC raised its stake in Zoetis Inc. (NYSE:ZTS) by 72.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 25,224 shares of the company’s stock after buying an additional 10,630 shares during the quarter. Diversify Wealth Management LLC’s holdings in Zoetis were worth $4,120,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Cherry Creek Investment Advisors Inc. grew its stake in shares of Zoetis by 2.0% in the third quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company’s stock worth $590,000 after purchasing an additional 58 shares during the last quarter. Grove Bank & Trust lifted its holdings in Zoetis by 0.5% during the 3rd quarter. Grove Bank & Trust now owns 11,763 shares of the company’s stock worth $2,298,000 after buying an additional 61 shares during the period. Hancock Whitney Corp grew its position in shares of Zoetis by 0.3% in the 3rd quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock valued at $3,628,000 after buying an additional 61 shares during the last quarter. Strategy Asset Managers LLC increased its stake in shares of Zoetis by 3.5% in the third quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock valued at $356,000 after buying an additional 62 shares during the period. Finally, Procyon Advisors LLC raised its position in shares of Zoetis by 1.4% during the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock worth $768,000 after acquiring an additional 63 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Down 2.0 %

Shares of Zoetis stock opened at $166.01 on Monday. The stock has a market capitalization of $74.90 billion, a PE ratio of 31.20, a price-to-earnings-growth ratio of 2.51 and a beta of 0.89. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53. The stock has a 50 day moving average price of $170.93 and a two-hundred day moving average price of $179.98. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter last year, the firm posted $1.36 EPS. Zoetis’s revenue was up 11.6% compared to the same quarter last year. As a group, equities analysts anticipate that Zoetis Inc. will post 5.91 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.20%. The ex-dividend date is Tuesday, January 21st. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s dividend payout ratio is currently 32.52%.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on ZTS shares. Leerink Partners assumed coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price for the company. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Stifel Nicolaus cut their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. JPMorgan Chase & Co. increased their price target on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Finally, UBS Group initiated coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $211.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.